(Axios) – At least half a dozen states are weighing new restrictions aimed at limiting pharmacy benefit managers’ ability to influence drug prices, including prohibitions on steering business to affiliated pharmacies.

Why it matters: With Congress gridlocked on PBM legislation, more states are taking the lead inaddressing industry practices that critics say drive up costs and are pushing independent pharmacies out of business. (Read More)